Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2025, Merit Medical (MMSI) reported revenue of $384.16 million, up 13% over the same period last year. EPS came in at $0.92, compared to $0.86 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $371.21 million, representing a surprise of +3.49%. The company delivered an EPS surprise of +12.2%, with the consensus EPS estimate being $0.82.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Merit Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Sales- International: $153.56 million versus the two-analyst average estimate of $149.53 million. The reported number represents a year-over-year change of +15.2%.
• Geographic Sales- APAC: $64.86 million compared to the $63.07 million average estimate based on two analysts. The reported number represents a change of +7.4% year over year.
• Geographic Sales- United States: $230.6 million versus $221.32 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11.7% change.
• Geographic Sales- Rest of World: $17.17 million compared to the $18.33 million average estimate based on two analysts. The reported number represents a change of +18.5% year over year.
• Geographic Sales- EMEA: $71.53 million compared to the $68.13 million average estimate based on two analysts. The reported number represents a change of +22.3% year over year.
• Revenue- Cardiovascular- Peripheral Intervention: $144.78 million compared to the $144.32 million average estimate based on five analysts. The reported number represents a change of +5% year over year.
• Revenue- Cardiovascular- Cardiac Intervention: $116.68 million versus $106.59 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +28.6% change.
• Revenue- Endoscopy: $17.73 million compared to the $18.47 million average estimate based on five analysts. The reported number represents a change of +4.4% year over year.
• Revenue- Cardiovascular- OEM: $50.83 million compared to the $50.46 million average estimate based on five analysts. The reported number represents a change of +17.2% year over year.
• Revenue- Cardiovascular: $366.43 million versus the five-analyst average estimate of $352.73 million. The reported number represents a year-over-year change of +13.5%.
• Revenue- Cardiovascular- Custom Procedural Solutions: $54.14 million versus the five-analyst average estimate of $51.38 million. The reported number represents a year-over-year change of +6.6%.

View all Key Company Metrics for Merit Medical here>>>

Shares of Merit Medical have returned -0.8% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research